search
Back to results

Gender Differences in the Metabolic Effects of Uric Acid

Primary Purpose

Hyperuricemia

Status
Withdrawn
Phase
Early Phase 1
Locations
United States
Study Type
Interventional
Intervention
low-fructose diet
Allopurinol
Sponsored by
University of Missouri-Columbia
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Hyperuricemia

Eligibility Criteria

40 Years - 70 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  1. Men and women with characteristics of the metabolic syndrome.
  2. 40-70 years of age
  3. Overweight/obese subjects with BMI 25.1 - 40.0 kg/m2
  4. Pre-diabetes defined as fasting glucose 100 - 125 mg/dL or 2h glucose 140 - 200 mg/dL
  5. Habitual diets containing ≥ 13.0% of energy from added sugars
  6. Serum uric acid ≥ 7.0 mg/dL for men and women

Exclusion Criteria:

  1. Renal dysfunction (defined by glomerular filtration rate [GFR] <60), abnormal thyroid function or liver disease
  2. Use of diuretics or azathioprine
  3. Diabetes defined as fasting glucose ≥ 125 mg/dL or HbA1c ≥ 7%
  4. Use of medications that interfere with lipid, protein, or carbohydrate metabolism, or occasional or regular tobacco use
  5. Habitual diets with low content of added sugars (<5% of total energy)
  6. History of gout , gouty arthritis, or uncontrolled hypertension
  7. Pregnant
  8. Vegetarian food restrictions (the diets consumed contain some meat, eggs and dairy)
  9. Alcohol intake: females > 70 g/wk, males >140 g/wk
  10. Inability to have an MRI

Sites / Locations

  • University of Missouri

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

No Intervention

Arm Label

low-fructose diet

allopurinol treatment

control arm

Arm Description

Intervention: low-fructose Subjects will consume a four-month diet with the goal of reducing added sugar intake from ≥13% of energy to <5% of energy and keeping their weight stable.

Subjects participating in the allopurinol treatment arm will begin with an initial dose of drug of 100 mg/d p.o. daily for 2 wks. The dose is then slowly increased over the next 8 wks to achieve a serum uric acid concentration of 6 mg/dL (maximum allopurinol dose is 800 mg/d). Once uric acid reaches 6 mg/dL, the subject stays on this dose and is seen for the interim visit (4 months), at which time all procedures are repeated. After this, drug treatment continues for another 4 months and the subject returns for the final visit at 8 months. The same procedures performed at baseline are repeated at this time. The dose of allopurinol will be taken the morning of the final visit.

After completion of the baseline visit (procedures described above), subjects participating in the control arm are not seen again until the 4-month time point, when the same procedures performed at baseline are repeated, except for the MRI. Following this, they are seen again at 8-months, when all baseline procedures are repeated. Cardiac MRI and labeled water consumption occur at the baseline and final visits.

Outcomes

Primary Outcome Measures

vessel stiffness
blood vessel stiffness is measured non-invasively with pulse wave velocity

Secondary Outcome Measures

Full Information

First Posted
March 1, 2017
Last Updated
April 15, 2019
Sponsor
University of Missouri-Columbia
search

1. Study Identification

Unique Protocol Identification Number
NCT03076684
Brief Title
Gender Differences in the Metabolic Effects of Uric Acid
Official Title
Gender Differences in the Metabolic Effects of Uric Acid
Study Type
Interventional

2. Study Status

Record Verification Date
April 2019
Overall Recruitment Status
Withdrawn
Why Stopped
Preliminary data collected and diets developed. Funding has ended and data used to support a larger application to test the hypothesis.
Study Start Date
March 3, 2017 (Actual)
Primary Completion Date
December 2018 (Anticipated)
Study Completion Date
March 13, 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Missouri-Columbia

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Increased stiffening of the heart and blood vessels is a predictor of heart disease. Stiffening has been found to be greater in women than men, which puts women with poor blood sugar control at a greater risk for heart disease than men. In women only, a molecule in the blood called uric acid can be elevated due to diets high in fructose consumption and it is thought to be a cause of heart and vessel stiffening. From previous research, we have found that restricting fructose in the diet lowers uric acid more in women than men. There is also a drug that can be used to lower uric acid. These findings suggest a potential approach to decrease vessel and heart stiffness in women. The present study will investigate fructose restriction in the diet and drug treatment to lower uric acid in the blood and its effects on heart disease risk in women compared to men.
Detailed Description
This project will use treatments from 4-8 months to lower uric acid in men and women. This study has three parts and each subject will participate in only one part. Tests that will be performed before and after treatment include measurements of body weight, blood pressure, blood vessel stiffness, heart stiffness, and blood lipids and glucose. Part 1: Dietary treatment The overall goal of part 1 is to remove fructose and simple sugars from the diets of women and men at risk for future heart disease. Dietary fructose will be replaced with starchy foods to keep the research subjects' body weights stable. Subjects will be treated for 4 months and measurements of vascular and heart stiffness will be made before, during, and after treatment. Part 2: Drug treatment The overall goal of part 2 is to treat women and men with mild elevations in blood uric acid for 8 months. The treatment will be allopurinol administration, ramping up the dose over a 2 month period to achieve a uric acid concentration of 6 mg/dL. Measurements of vascular and heart stiffness will be made before, during, and after. Part 3: Control, no treatment These individuals will undergo the same baseline and follow-up tests as the other two parts but have no treatments. Tests that will be completed before and after

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hyperuricemia

7. Study Design

Primary Purpose
Basic Science
Study Phase
Early Phase 1
Interventional Study Model
Parallel Assignment
Model Description
There are three arms of this study: a diet-treated group, a drug-treated group and a control group.
Masking
None (Open Label)
Allocation
Randomized
Enrollment
0 (Actual)

8. Arms, Groups, and Interventions

Arm Title
low-fructose diet
Arm Type
Experimental
Arm Description
Intervention: low-fructose Subjects will consume a four-month diet with the goal of reducing added sugar intake from ≥13% of energy to <5% of energy and keeping their weight stable.
Arm Title
allopurinol treatment
Arm Type
Experimental
Arm Description
Subjects participating in the allopurinol treatment arm will begin with an initial dose of drug of 100 mg/d p.o. daily for 2 wks. The dose is then slowly increased over the next 8 wks to achieve a serum uric acid concentration of 6 mg/dL (maximum allopurinol dose is 800 mg/d). Once uric acid reaches 6 mg/dL, the subject stays on this dose and is seen for the interim visit (4 months), at which time all procedures are repeated. After this, drug treatment continues for another 4 months and the subject returns for the final visit at 8 months. The same procedures performed at baseline are repeated at this time. The dose of allopurinol will be taken the morning of the final visit.
Arm Title
control arm
Arm Type
No Intervention
Arm Description
After completion of the baseline visit (procedures described above), subjects participating in the control arm are not seen again until the 4-month time point, when the same procedures performed at baseline are repeated, except for the MRI. Following this, they are seen again at 8-months, when all baseline procedures are repeated. Cardiac MRI and labeled water consumption occur at the baseline and final visits.
Intervention Type
Other
Intervention Name(s)
low-fructose diet
Intervention Description
Subjects will consume a four-month diet with the goal of reducing added sugar intake from ≥13% of energy to <5% of energy and keeping their weight stable.
Intervention Type
Drug
Intervention Name(s)
Allopurinol
Intervention Description
Subjects in the drug arm will take the drug allopurinol daily.
Primary Outcome Measure Information:
Title
vessel stiffness
Description
blood vessel stiffness is measured non-invasively with pulse wave velocity
Time Frame
Change from baseline at 4 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
40 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Men and women with characteristics of the metabolic syndrome. 40-70 years of age Overweight/obese subjects with BMI 25.1 - 40.0 kg/m2 Pre-diabetes defined as fasting glucose 100 - 125 mg/dL or 2h glucose 140 - 200 mg/dL Habitual diets containing ≥ 13.0% of energy from added sugars Serum uric acid ≥ 7.0 mg/dL for men and women Exclusion Criteria: Renal dysfunction (defined by glomerular filtration rate [GFR] <60), abnormal thyroid function or liver disease Use of diuretics or azathioprine Diabetes defined as fasting glucose ≥ 125 mg/dL or HbA1c ≥ 7% Use of medications that interfere with lipid, protein, or carbohydrate metabolism, or occasional or regular tobacco use Habitual diets with low content of added sugars (<5% of total energy) History of gout , gouty arthritis, or uncontrolled hypertension Pregnant Vegetarian food restrictions (the diets consumed contain some meat, eggs and dairy) Alcohol intake: females > 70 g/wk, males >140 g/wk Inability to have an MRI
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Elizabeth Parks, PhD
Organizational Affiliation
University of Missouri-Columbia
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Missouri
City
Columbia
State/Province
Missouri
ZIP/Postal Code
65212
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Gender Differences in the Metabolic Effects of Uric Acid

We'll reach out to this number within 24 hrs